Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 12/20 | 0.55 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.40 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.40 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29386366 | 0.86 | FGFR1 (0.52) | FGFR1SRCFGFR2FGFR4FGFR3 | |
| SCHEMBL16668439 | 0.86 | FGFR1 (0.52) | FGFR1SRCFGFR2FGFR4FGFR3 | |
| SCHEMBL16667875 | 0.86 | FGFR1 (0.52) | FGFR1SRCFGFR2FGFR4FGFR3 | |
| SCHEMBL24336038 | 0.79 | FGFR1 (0.46) | FGFR1SRCFGFR2FGFR4FGFR3 | |
| SCHEMBL28282206 | 0.71 | EGFR (0.57) | NPC1RAB9A | |
| SCHEMBL28843889 | 0.71 | ALDH1A1 (0.62) | GAAMAPT | |
| SCHEMBL16667808 | 0.71 | FGFR1 (0.55) | FGFR1SRCFGFR2FGFR4FGFR3 | |
| SCHEMBL29385006 | 0.71 | FGFR1 (0.55) | FGFR1SRCFGFR2FGFR4FGFR3 | |
| Hydrochloric Acid SCHEMBL28048118 | 0.70 | EGFR (0.56) | NPC1RAB9A | |
| SCHEMBL29385053 | 0.70 | KDM4E (0.65) | FGFR1SRCFGFR2FGFR4FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10875837-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200109127-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION (US) | 2020-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200109127-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR4, FGFR1, FGFR2 | FGFR1 2/4885SRC 39/4885FGFR2 3/4885 |
| US-10875837-B2 | Inhibitors of the fibroblast growth factor receptor | FGFR4, FGFR1, FGFR2 | FGFR1 2/4885SRC 39/4885FGFR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.